of antibodies against tumor-associated antigens, such as AFP or CEA, for the diagnosis and management of malignant diseases. The measurement of serum antigen level has been demonstrated to be one of the useful methods not only to detect the presence of malignancy but to monitor the disease state after each therapeutic procedure. A number of human pancreatic cancer-associated antigens have already been described and analyzed both experimentally and clinically using polyclonal xenoantisera (Banwo et al. 1974 ; Schultz and Yunis 1976 ; Gelder et al. 1978 ; Holyoke et al. 1979 ; Hobbs 1980 ; Zamcheck 1981 ). However, the clinical application of these antigens for the early detection of pancreatic cancer has not yet been performed successfully because of the wide cross reactivity and the low sensitivity of the antisera (Banwo et al. 1974 ; Schultz and Yunis 1976; Gelder et al. 1978; Hobbs 1980 ). On the other hand, since the introduction of somatic cell hybridization (Kohler and Milstein 1975) , a number of monoclonal antibodies against a variety of human tumors, such as melanoma ; Liao et al. 1982; Natali et al. 1982) , lung cancer (Kasai et al. 1981 ; Brown and Moore 1982; Mazauric et al. 1982; Bernal and Speak 1984) , breast cancer (Menard et al. 1983 ; Papsidero et al. 1983 ), colorectal cancer ; Atkinson et al. 1982 ; Thompson et al. 1983 ; Kaszubowski et al. 1984) , and prostate and bladder cancer (Starling et al. 1982 ; Masuko et al. 1985) have been produced. It is expected that these monoclonal antibodies can be more useful for evaluating the distribution of organ-specific antigens or tissue-associated antigens and for detecting potential tumor-associated antigens in cancer patients because of the high reaction specificity. These circumstances urged us to establish human pancreatic cancer cell lines and to elaborate monoclonal antibodies specific for pancreatic cancer cells.
In the present report, we describe the production and the characterization of the monoclonal antibody F30 which is reactive with pancreatic cancer cell PK-1. And we evaluate the reaction specificity of this antibody with a panel of various tumor cell lines and frozen sections of tumor and normal tissues, and further estimate the molecular profile of the antigens recognized by the F30.
MATERIALS AND METHODS

Cell lines used for immunization and screening of monoclonal antibody
Human pancreatic cancer cell line PK-1 established in our laboratory (Kobari et al. 1984 ) was used for the immunization. This cell line was initiated from a papillotubular adenocarcinoma obtained from a liver metastasis of the carcinoma of the pancreatic body. After trypsinization, PK-1 cells were washed three times with PBS, and 1 x 10 ' cells in 0.5 ml PBS were prepared for intraperitoneal immunization. Human cell lines used for the screening of monoclonal antibodies were as follows : pancreatic cancer cell lines PK-8, PK-9, PK-12, PK-14, PK-16 were established in our laboratory ; gastric cancer cell lines KATO-3 and M74-1, colon cancer cell lines 57512 and M7609, and esophagus cancer cell lines TE-1 and TE-4, were kindly provided by Dr. S. Nishihira ; lung cancer cell lines LK-2-18 and LK-2-51 and melanoma cell line Met-2-42 were kindly provided by Dr. S. Kobayashi ; breast cancer cell line MMK-K was established in our laboratory from xenografted breast cancer in nude mice and another breast cancer cell line CRL-1500 was purchased from Flow Laboratories (North Ryde, N.S.W., Australia) ; hepatoma cell line HuH-7 was kindly provided by H. Nakabayashi (Nakabayashi et al. 1984 ) and HT-1 was established in our laboratory from xenografted hepatoma Li-7 in nude mice kindly provided by Dr. S. Hirohashi (Hirohashi et al. 1979 ) ; other cell lines used in this study have been maintained in our laboratory.
Production of monoclonal antibodies
Immunization and somatic cell hybridization. BALB/C mice were immunized intraperitoneally with two bi-weekly injections of PK-1 cells and followed by a final booster intraperitoneal injection 3 days prior to the cell fusion. Immune spleen cells (5 X 10') were fused with 5 X 106 P3-X63-Ag8-653 murine myeloma cells in the presence of 45% polyethylene glycol 1,000 in MEM according to the method of Kohler and Milstein (Kohler and Milstein 1975 ) with some modifications.
Selection of hybridoma. After fusion, cells were cultured in HAT medium (hypoxantine, aminopterin, thymidine) at 37°C in 5% CO2 in humidified atmosphere. Cloning of hybrid cells reactive with the target PK-1 cells was carried out by the limiting dilution at the cell density ranging from 5/ml to 10 ml with thymocytes as a feeder layer and repeated 2 or 3 times. Cloned hybrid cells secreting antibody reactive with PK-1 cells by IIF were implanted into BALB/C mice intraperitoneally to obtain sera and ascites. The monoclonal antibody produced by one cloned hybridoma, designated F30 was used in the present study.
Antibody detection assays
Indirect immunoluorescence. The culture supernatant of hybridoma was used for the evaluation of the anti-PK-1 cell antibody. At first, 5 x 105 PK-1 cells in each tube were incubated with 50,u1 of hybridoma supernatant at 37°C for 30 min. After three washes with old PBS containing 0.01% sodium azide, the cells were incubated with 50 pl of FITC conjugated anti-mouse Ig (MBL, Nagoya) at 37°C for 30 min. After three washes, the membrane fluorescence was determined with an epi-illumination fluorescence microscope (Zeiss, West Germany). The membrane CEA of cell lines was also assayed by IIF using rabbit anti-CEA immunoglobulin (DAKO-Immunoglobulins, Copenhagen, Denmark) and FITC conjugated anti-rabbit IgG (Hoechst Behring Institute, Marburg-Lahn, FRG).
Enzyme-linked immunosorbent assay (ELISA). ELISA was carried out for the screening of the immunoglobulin secretion of hybridoma into the culture supernatant. Target PK-1 cells, 5 x 105 per tube, were first incubated with 50 p1 of the hybridoma culture supernatant diluted to 1/50 with the medium at 37°C for 30 min. After three washes with cold PBS, the cells were incubated at 37°C for 30 min with 50 ~cl of peroxidase-conjugated anti-mouse Ig (DAKO-Immunoglobulins, Copenhagen, Denmark) at dilution of 1/500 in 1% BSA containing RPMI 1640 medium. After 4 washes with cold PBS, 100 l of substrate solution (10 ml of 0.1 M citrate buffer, pH 4.5, 10 mg of 0-phenylenediamine (Sigma Chemical Company, St. Louis, MO, USA) 4,u1 of 30% H2O2 stock solution) was added to the tube and incubated at 37°C for 30 min in the dark. Enzymatic reaction was stopped by adding 50 p 1 of 6N-H2 SO4 and the optimal density of the colored supernatant was measured at 500 nm by a spectrophotometer.
Absorption tests
Reactivities of F30 with various tumor cell lines were examined first by IIF. And then the following absorption tests were performed for cell lines when IIF were negative.
ELISA. F30 (1/50 in medium) was absorbed with various tumor cell lines for 30 min. at 37°C and another 30 min. at 4°C. After centrifugation, the remaining activity of F30 was determined with target PK-1 cells by ELISA as mentioned before.
Indirect immunofluorescence. McAb F30 (diluted to 1/40 in medium) was absorbed with a CEA producing gastric cancer cell line, KATO-3 (Sekiguchi et al. 1978 ) for 30 min.
at 37°C and then for 30 min at 4°C. The absorbed F30 was also tested for the remaining activity to PK-1 cells by IIF.
Absorption test with PK-1 cell spent culture medium. One volume of diluted F30 (1/ 25) was mixed with an equal volume of the concentrated serum free spent culture medium of PK-1 cells and allowed to stand for 18 hr at 4°C. The mixture was tested for the remaining antibody activity by ELISA.
Purification of monoclonal antibody and iodination
The isotype of monoclonal antibody was determined by the double immunodiffusion method using goat anti-mouse immunoglobulins (.1eloy laboratories, Inc. Diagnosis Division, Springfield, VA., USA). Enzyme treatment PK-1 cells were incubated with enzymes at 37°C for one hr and then examined for the expression of the F30 reactve antigen by IIF or absorption tests with ELISA. Enzymes used in this assay were neuraminidase (Hoechst), trypsin (GIBCO, Grand Island, NY, USA), pronase (Kaken Co., Ltd, Tokyo), deoxyribonuclease (Millipore Corporation, Freehold, N.J., USA), and collagenase (Millipore Corporation).
Immunoprecipitation and SDS-PAGE
Radioiodination of cell membrane. Viable PK-1 cell suspension at 3 X 10a cells in 0.1 ml PBS was mixed with 100,ul of lactoperoxidase (Sigma chemical Co.) at 1 mg ml in PBS, pH 7.3, 2 mCi of 1251-NaI in 20 l, and finaly 100,ul of freshly prepared 11202 solution (0.03° ) in PBS. The mixture was left at 30°C for 5 min. Aliquots of lactoperoxidase and freshly prepared 11202 solution were then added again and incubated for 5 min. This step was repeated three times. After 5 minutes' incubation, the cells were washed three times with PBS and resuspended in 0.5 ml PBS.
A subconfluent monolayer of PK-1 cells was also intrinsically radiolabeled with 300 to Pancreatic Cancer 183
,uCi of 35S-methionine in MEM without unlabeled methionine overnight at 37°C (Bumol and Reisfeld 1982) . Labeled cells were harvested with 0.25% trypsin treatment, washed three times and suspended in 0.5 ml PBS. Membrane extraction. A half ml of extraction buffer (1% NP-40,1 mM PMSF in PBS, pH 7.3) was added to 0.5 ml of cell suspension in PBS and vigorously mixed on ice for 30 min. Extracts were cleared by centrifugation once at 2,000 X g for 15 minutes and again at 25,000 x g for 1 hr.
Immunoprecipitation. One ml of 10% Zysorbin (fixed and killed protein-A bearing staphylococcus aureus ; Zymed Labo., Burlingame, CA, USA) was washed 3 times with washing buffer (0.1% BSA, 0.02% sodium azide, 0.5% NKP-40, 0.1% SDS in PBS, pH 8. 6). To this pelleted Zysorbin, 1 ml of anti-mouse Ig was added. After incubation for 30 min at 37°C, the Zysorbin was washed 4 times with washing buffer (WB). Next, F30 or anti-human IgM McAb, KM-8 as a control were added to the zysorbin pellet and incubated for 1 hr at 37°C. After washing 3 times with WB,125I-labeled cell extract or 355-methionine labeled cell extract was added to the Zysorbin pellet coupled with McAb and incubated overnight at 4°C with a continuous rotation.
SDS-PAGE. The Zysorbin-antigen complex was washed 3 times with WB, and then the pellet was resuspended in 501al of sample buffer (4 M urea, 20 mM IAA, 0.25% BPB, 2% SDS, 50% glycerol with or without 0.1% 2-mercaptoethanol in 0.02 M phosphate buffer). This mixture was heated at 100°C for 2 min. Electrophoresis on 7% polyacrylamide gel was carried out as described by Galloway et al. (1981) and followed by autoradiography.
Indirect immunofluorescence of tissue sections
At the beginning, 4,im cryostat sections were pretreated with 10% normal horse serum for 15 min at room temperature. After washing of sections with PBS, McAb F30 (not diluted) was added on tissue sections. Preculture medium or anti-human IgM McAb KM-8 was used as a control. After incubation for 30 min at 37°C and rinsing in PBS, sections were incubated with biotinylated horse anti-mouse Ig antisera (Vector Labs Inc. Burlingame, CA., USA) at 1/100 dilution for 30 min at room temperature. After rinsing in PBS sections were incubated with FITC conjugated avidin at 1/50 dilution for 30 min at room temperature, and examined under the epi-illumination fluorescence microscope.
In immunoperoxidase staining using ABC system, biotinylated secondary antibody and next avidin-biotin conjugated horseradish peroxidase (Vector Labs) were incubated for 30 min at 37°C after the slides were first incubated with McAb F30. Then the slides were incubated with enzyme substrate solution (30 mg diaminobenzidine (Sigma Chemical Co.) and 0.15 ml of 5% 11202 in 150 ml of 0.05 M Iris buffer pH 7.2) for up to 10 min at room temperature and examined for staining.
RESULTS
By the fusion of x 63 myeloma cell with spleen cells of a BALB/C mouse immunized with pancreatic cancer cell line PK-1, 23 colonies secreting antibodies reactive with PK-1 cells were obtained. After cloning of these colonies, three clones specifically reactive with PK-1 cells were selected. Among these colonies C-8 was abandoned because of low reactivity, F-11 was lost by contamination, and only clone F30 was maintained.
Culture supernatant of this clone F30 was used as McAb to pancreatic cancer in this study. Clear immunofluorescent staining pattern was visible on the membrane of PK-1 cells in IIF with McAb F30 (Fig.  1) . (Fig. 3) . McAb F30 was not absorbed by CEA positive cells at all. In addition, it was tested whether CEA formed co-cap with the F30 defined antigen. As shown in the figure 2, F30 antigen was stained green and capped over the upper surface of PK-1 cell (upper left of the figure), while CEA was stained red and destributed equally circular over the cell surface (right part of the figure). These data clearly indicate that F30 defined antigen is not identical with CEA.
Binding inhibition tests
Next, it was studied whether the binding of McAb F30 was inhibited by antibodies to several other surface antigens to clarify the relationship between the F30 defined antigens and other surface antigens. For this purpose, a panel of unlabelled antibodies as competitors were preincubated with target PK-1 cells before reaction with '25I-labeled McAb F30 (Table 3 ). The binding of McAb F30 was inhibited neither by control McAb KM-8 (anti-human IgM) nor by other antibodies to CEA, AFP, ferritin, f2-microglobulin, and HLA. So it was suggested that F30 was not reactive with other antigenic determinants, at least such as, CEA, AFP, ferritin, HLA-DR-Ag, 2-microglobulin, and HLA. was performed by ELISA (Fig. 4) . The activity of F30 against PK-1 was not affected after absorption with 20 times concentrated spent culture medium indicating that PK-1 cells secreted no F30 reactive antigen or, if any, it was undetectable amount in the medium.
Immunoprecipitation and SDS-PAGE
Results obtained by immunoprecipitation analysis of the detergent extract of 1251-labeled PK -1 cells are shown in Fig . 5 . McAb F30 detected two specific protein components of molecular weight of 190 K and 160 K dalton. The component of 40 K was not specific because this component was also detected in the immunoprecipitate with control McAb KM-8. These two specific components and one non-specific component were more clearly shown in y-counting pattern of sliced gels (the right part of Fig. 5 ). Specific components gave strong counts while the count of non-specific one was weak.
Analysis of detergent extract from PK-1 cells intrinsically labelled with 355-methionine by immunoprecipitation and SDS-PAGE demonstrated the presence of a component of 200 K dalton which reacted with McAb F30 (Fig. 5) . This component is slightly larger than 190 K component of '251-labelled cell extract. It is not clear whether these two components are identical.
Enzyme sensitivity of F30 reactive antigen on PK-1 cells
The antigen detected by McAb F30 was found to be resistant to the treatment with several enzymes including neuraminidase and proteases (Table 4 ). The F30 reactive antigen expression was moderately decreased by the treatment with neuraminidase or trypsin only when both were used at very high concentrations. Deoxyribonuclease and collagenase had no marked influence on the antigen 
Immunoreactivity of normal and malignant tissue sections with McAb F30
Immunofluorescence staining with biotin-avidin system was performed using fresh frozen sections because the ordinary IIF staining on formalin fixed paraffinembedded sections could not show the positive reaction (Table 5) . Immunoperoxidase staining was next performed for histological analysis. In pancreatic cancer, all specimens showed positive reactions on their cancer cell membranes. There were no reactions in the surrounding interstitial tissue. Similar reactions on the cancer cell membranes were detected in stomach cancer, colon cancer, and breast cancer. In the distribution analysis of normal tissues, McAb F30 reacted at first with cell membranes of squamous epithelium of the skin and esophagus. Though the reaction was lost in the stomach, it was found again on glandular epithelial cell membranes in the duodenum, small intestine, and colon. No reaction was detected in the liver. The weak reaction was also seen on cell membranes in the gallbladder and the common bile duct and the pancreatic duct cell membranes were equally positive. In other tissues, positive reactions were shown on the columnar epithelium of the trachea, but not definite in the lung. Similar membrane staining was also detected in the tubular epithelial cells of the kidney and the transitional epithelium of the urinary bladder. No reaction was detected in the lymphoid tissues.
DISCUSSION
We prepared and selected a monoclonal antibody (McAb F30) directed against the established human pancreatic cancer cell, PK-1. The isotype of the monoclonal antibody was IgG2b. Since PK-1 cells used for immunization was positive for CEA, fl2-microglobulin and HLA, it was necessary to clarify whether McAb F30 is an antibody directed to these antigens. From the results of the binding inhibition assay of 1251-labeled McAb F30, it was shown that F30 directed to neither $2-microglobulin nor HLA-associated antigens such as shared HLA and HLA-DR antigens (Table 3 ). It is clear that F30 reactive antigen is different from HLA, because F30 failed to react with lymphoblastoid cell lines and normal lymphocytes (Table 1) . It is also evident from the data in Table 2 and Fig. 4 that F30 reactive antigen is neither blood type antigens nor fetal bovine serum components. As for the relationship between F30 reactive antigen and CEA, McAb F30 was not absorbed with gastric cancer cell line KATO-3 which was strongly CEA positive (Fig. 3) . Furthermore, CEA was not co-capped with F30 reactive antigen (Fig. 2) . Therefore, it was concluded that F30 reactive antigen was entirely different from CEA.
F30 strongly reacted with all of six established pancreatic cancer cell lines. In addition to this specific reactivity with pancreatic cancer cells, the monoclonal antibody showed cross reactivity with a colon cancer cell line M7609 and an esophagus cancer cell line TE-1. In addition to that, the absorption test demonstrated cross-reactivities with an esophagus cancer cell line TE-4 and human embryonal lung fibroblast, although these cell lines did not show apparent positive immunofluorescence. On the other hand, McAb F30 failed to react with gastric cancer, hepatoma, lung cancer, brain tumor, melanoma, and breast cancer cell lines listed in Table 1 .
Tumor associated antigens of embryonic origin including AFP and CEA have been described in variety of tumors (Gold and Freedman 1965; Abelv 1976; Sega et al. 1979; Pant et al. 1982) . Oncofetal antigens of pancreatic cancer have also been described by using xenoantisera specific for fetal pancreas (Banwo et al. 1974; Gelder et al. 1978; Hobbs 1980 ). Metzgar et al. (1982) detected antigens of human pancreatic adenocarcinoma cells by several murine monoclonal antibodies. One of these monoclonal antibodies reacted with fetal tissues in addition to pancreatic tumors. Therefore, it is possible that McAb F30 reacts with a kind of oncofetal antigen expressed on PK-1 cells. However, it is too early to conclude that F30-reactive antigen is oncofetal only from the cross-reactivity with cultured embryonic fibroblasts, because the cultured cell line may have aquired antigens which were not present in fetal tissues. Pancreatic oncofetal antigens reported so far have been detected in sera of patients with pancreatic cancer, suggesting that the relevant antigens are secreted or shed from tumor cells (Banwo et al. 1974; Gelder et al. 1978 ; Hobbs 1980) . But the F30-reactive antigen was not detected in the concentrated serum-free spent medium of PK-1 cell culture (Fig. 4) . Therefore the F30-reactive antigen may be an integral protein in the cell membrane and non-secretory one.
Studies on immunoreactivity with various normal and malignant tissue sections indicated that McAb F30 reacted not only with adenocarcinomas of various organs, but also with normal epithelial cell membranes from various tissues including gastrointestinal organs, respiratory system, aand urinary system (Table 5 ). This reaction specificity is very similar to that of McAb C50-4 produced by Schmiegel et al. (1985) . They also reported McAb CI-P83 against pancreatic cancer with more specific reactivity. The difference in reaction specificity on various epithelial cells raises the possibility that epithelial cell subsets may exist as indicated in several reports ; Thompson et al. 1983 ). This tissue distribution of F30-reactive antigen on epithelial cell membranes is closely related to the reaction specificity of McAb F30 with established cancer cell lines. These reaction positive cultured cancer cells may retain the same antigenicity of their original tissue antigen. Since the reaction with McAb F30 is mostly found in differentiated types of adenocarcinomas both in vitro and in frozen tissue sections, F30-reactive antigen may also have characteristics of differentiation antigen similar to CEA which has been shown to be produced in larger quantities in more differentiated type of adenocarcinomas (Zamcheck 1981) . In addition to that, there is a possibility that even a reaction negative tissue may begin to express the tissue associated antigen in accordance with their malignant change. The gastric cancer tissue showed positive reaction while it was negative in the normal gastric mucosa (Table 5 ). This reaction distribution in various normal tissues is vary similar to reaction specificity of the monoclonal antibody which were shown to be reactive with the differentiation antigen of epithelial cells (Atkinson et al. 1982 ; Croghan et 1.1983 ; Menard et al. 1983 ; Thompson et al. 1983) .
It is interesting to note that the F30-reactive antigen is not detected in the liver and is not a secreted type antigen, indicating that McAb F30, if conjugated with anti-tumor drugs, may be useful as a specific immunotherapeutic agent to prevent liver metastasis.
In preliminary molecular characterization of F30-reactive antigen by immnuoprecipitation and SDS-PAGE, two peptide components with molecular weight of 190 k and 160 k were detected. It is not clear why two components are reactive with McAb F30. One possibility is that two components were separated by the treatment with SDS and urea (Mazauric et al. 1982) . Alternatively two different components on the cell surface share the same antigenic determinants reactive with McAb F30. One component labeled with 35S-methionine was faintly seen and estimated to be approximately 200 k dalton. This 200 K component may be the same to 190 K component (Fig. 5) . Considering from low sensitivity of F30-reactive antigen to neuraminidase, the antigen does not seem to be associated with sialic acid. Further studies on the characterization of the antigen defined by the monoclonal antibody and the detailed distribution of the antigen in tissues including various malignant and fetal tissues are needed.
